Literature DB >> 25953702

Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases.

Ashley R Maiuri1, Anna B Breier2, Lukas F J Gora2, Robert V Parkins2, Patricia E Ganey2, Robert A Roth2.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of idiosyncratic, drug-induced liver injury (IDILI). Mechanisms of IDILI are unknown, but immune responses are suspected to underlie them. In animal models of IDILI, the cytokines tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) are essential to the pathogenesis. Some drugs associated with IDILI interact with cytokines to kill hepatocytes in vitro, and mitogen-activated protein kinases (MAPKs) might play a role. We tested the hypothesis that caspases and MAPKs are involved in NSAID/cytokine-induced cytotoxicity. NSAIDs that are acetic acid (AA) derivatives and associated with IDILI synergized with TNFα in causing cytotoxicity in HepG2 cells, and IFNγ enhanced this interaction. NSAIDs that are propionic acid (PA) derivatives and cause IDILI that is of less clinical concern also synergized with TNFα, but IFNγ was without effect. Caspase inhibition prevented cytotoxicity from AA and PA derivative/cytokine treatment. Treatment with a representative AA or PA derivative induced activation of the MAPKs c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38. Inhibition of either JNK or ERK reduced cytotoxicity from cytokine interactions with AA derivatives. In contrast, an ERK inhibitor potentiated cytotoxicity from cytokine interactions with PA derivatives. An AA derivative but not a PA derivative enhanced IFNγ-mediated activation of STAT-1, and this enhancement was ERK-dependent. These findings raise the possibility that some IDILI reactions result from drug/cytokine synergy involving caspases and MAPKs and suggest that, even for drugs within the same pharmacologic class, synergy with cytokines occurs by different kinase signaling mechanisms.
© The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ERK; JNK; NSAID; cytokine; idiosyncratic drug-induced liver injury

Mesh:

Substances:

Year:  2015        PMID: 25953702      PMCID: PMC4607747          DOI: 10.1093/toxsci/kfv091

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  43 in total

Review 1.  ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence.

Authors:  Sebastien Cagnol; Jean-Claude Chambard
Journal:  FEBS J       Date:  2009-10-16       Impact factor: 5.542

2.  Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.

Authors:  Benjamin D Cosgrove; Leonidas G Alexopoulos; Ta-chun Hang; Bart S Hendriks; Peter K Sorger; Linda G Griffith; Douglas A Lauffenburger
Journal:  Mol Biosyst       Date:  2010-04-01

3.  Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis.

Authors:  Christine M Dugan; Aaron M Fullerton; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2011-01-18       Impact factor: 4.849

4.  Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-26       Impact factor: 4.030

5.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.

Authors:  Iwona Sadzak; Melanie Schiff; Irene Gattermeier; Reingard Glinitzer; Ines Sauer; Armin Saalmüller; Edward Yang; Barbara Schaljo; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

6.  Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury.

Authors:  Wei Zou; Kevin M Beggs; Erica M Sparkenbaugh; A Daniel Jones; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2009-07-28       Impact factor: 4.030

7.  Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.

Authors:  Patrick J Shaw; Amy C Ditewig; Jeffrey F Waring; Michael J Liguori; Eric A Blomme; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2008-10-16       Impact factor: 4.849

8.  Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.

Authors:  Benjamin D Cosgrove; Bracken M King; Maya A Hasan; Leonidas G Alexopoulos; Paraskevi A Farazi; Bart S Hendriks; Linda G Griffith; Peter K Sorger; Bruce Tidor; Jinghai J Xu; Douglas A Lauffenburger
Journal:  Toxicol Appl Pharmacol       Date:  2009-04-09       Impact factor: 4.219

Review 9.  Measurement of total lactate dehydrogenase activity.

Authors:  R E Vanderlinde
Journal:  Ann Clin Lab Sci       Date:  1985 Jan-Feb       Impact factor: 1.256

10.  Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers.

Authors:  Peter Bramlage; Adrian Goldis
Journal:  BMC Pharmacol       Date:  2008-10-29
View more
  8 in total

Review 1.  Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways.

Authors:  Daniel L Villeneuve; Brigitte Landesmann; Paola Allavena; Noah Ashley; Anna Bal-Price; Emanuela Corsini; Sabina Halappanavar; Tracy Hussell; Debra Laskin; Toby Lawrence; David Nikolic-Paterson; Marc Pallardy; Alicia Paini; Raymond Pieters; Robert Roth; Florianne Tschudi-Monnet
Journal:  Toxicol Sci       Date:  2018-06-01       Impact factor: 4.849

Review 2.  Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management.

Authors:  M Mosedale; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  2017-01-11       Impact factor: 6.875

3.  Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.

Authors:  Ashley R Maiuri; Bronlyn Wassink; Jonathan D Turkus; Anna B Breier; Theresa Lansdell; Gurpreet Kaur; Sarah L Hession; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2017-07-07       Impact factor: 4.030

4.  Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury.

Authors:  Robert A Roth; Omar Kana; David Filipovic; Patricia E Ganey
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-08-24       Impact factor: 4.936

Review 5.  Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.

Authors:  Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson
Journal:  Int J Toxicol       Date:  2020 Mar/Apr       Impact factor: 2.032

6.  Calcium Contributes to the Cytotoxic Interaction Between Diclofenac and Cytokines.

Authors:  Ashley R Maiuri; Anna B Breier; Jonathan D Turkus; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2015-11-24       Impact factor: 4.849

Review 7.  In Vitro Models for Studying Chronic Drug-Induced Liver Injury.

Authors:  M Teresa Donato; Gloria Gallego-Ferrer; Laia Tolosa
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

Review 8.  Dissecting the molecular pathophysiology of drug-induced liver injury.

Authors:  Hui Ye; Leonard J Nelson; Manuel Gómez Del Moral; Eduardo Martínez-Naves; Francisco Javier Cubero
Journal:  World J Gastroenterol       Date:  2018-04-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.